<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35121850</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pediatric research</Title><ISOAbbreviation>Pediatr Res</ISOAbbreviation></Journal><ArticleTitle>Milrinone effects on cardiac mitochondria, hemodynamics, and death in catecholamine-infused rats.</ArticleTitle><Pagination><StartPage>1309</StartPage><EndPage>1315</EndPage><MedlinePgn>1309-1315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41390-022-01964-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Catecholamine-storm is considered the major cause of enterovirus 71-associated cardiopulmonary death. To elucidate the effect of milrinone on cardiac mitochondria and death, a rat model of catecholamine-induced heart failure was investigated.</AbstractText><AbstractText Label="METHODS">Young male Spray-Dawley rats received a continuous intravenous infusion of norepinephrine then followed by co-treatment with and without milrinone or esmolol. Vital signs were monitored and echocardiography was performed at indicated time points. At the end of experiments, hearts were extracted to study mitochondrial function, biogenesis, and DNA copy numbers.</AbstractText><AbstractText Label="RESULTS">Hypernorepinephrinemia induced persistent tachycardia, hypertension, and high mortality and significantly impaired the activities of the electron transport chain and suppressed mitochondrial DNA copy number, mitochondrial transcription factor A and peroxisome proliferator-activated receptor-gamma coactivator 1-&#x3b1;. Norepinephrine-induced hypertension could be significantly suppressed by milrinone and esmolol. Milrinone improved but esmolol deteriorated the survival rate. The left ventricle was significantly enlarged shortly after norepinephrine infusion but later gradually reduced in size by milrinone. The impairment and suppression of mitochondrial function could be significantly reversed by milrinone but not by esmolol.</AbstractText><AbstractText Label="CONCLUSIONS">Milrinone may protect the heart via maintaining mitochondrial function from hypernorepinephrinemia. This study warrants the importance of milrinone and the preservation of mitochondrial function in the treatment of catecholamine-induced death.</AbstractText><AbstractText Label="IMPACT">Milrinone may protect the heart from hypernorepinephrinemia-induced death via maintaining myocardial mitochondrial activity, function, and copy number. Maintenance of cardiac mitochondrial function may be a potential therapeutic strategy in such catecholamine-induced heart failure.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>I-Chun</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. mslinichun@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ying-Jui</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Mao-Hung</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Kai-Sheng</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Shuang Ho Hospital-Taipei Medical University, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Julie Y H</ForeName><Initials>JYH</Initials><AffiliationInfo><Affiliation>Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Kay L H</ForeName><Initials>KLH</Initials><AffiliationInfo><Affiliation>Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. wlh0701@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Senior Citizen Services, National Tainan Institute of Nursing, Tainan, Taiwan. wlh0701@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Res</MedlineTA><NlmUniqueID>0100714</NlmUniqueID><ISSNLinking>0031-3998</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JU9YAX04C7</RegistryNumber><NameOfSubstance UI="D020105">Milrinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>MDY902UXSR</RegistryNumber><NameOfSubstance UI="C036604">esmolol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020105" MajorTopicYN="N">Milrinone</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008929" MajorTopicYN="N">Mitochondria, Heart</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35121850</ArticleId><ArticleId IdType="pmc">PMC8814569</ArticleId><ArticleId IdType="doi">10.1038/s41390-022-01964-6</ArticleId><ArticleId IdType="pii">10.1038/s41390-022-01964-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fu YC, et al. Cardiac complications of enterovirus rhombencephalitis. Arch. Dis. Child. 2004;89:368&#x2013;373. doi: 10.1136/adc.2003.029645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/adc.2003.029645</ArticleId><ArticleId IdType="pmc">PMC1719879</ArticleId><ArticleId IdType="pubmed">15033850</ArticleId></ArticleIdList></Reference><Reference><Citation>Spapen J, de Filette J, Lochy S, Spapen H. Acute heart failure as a first presentation of pheochromocytoma complicated with &#x201c;inverted&#x201d; Takotsubo syndrome. Case Rep. Endocrinol. 2020;2020:2521046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103034</ArticleId><ArticleId IdType="pubmed">32257461</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, et al. Prevalence and patterns of left ventricular dysfunction in patients with pheochromocytoma. J. Cardiovasc. Ultrasound. 2011;19:76&#x2013;82. doi: 10.4250/jcu.2011.19.2.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.4250/jcu.2011.19.2.76</ArticleId><ArticleId IdType="pmc">PMC3150700</ArticleId><ArticleId IdType="pubmed">21860721</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, Li H. The science underlying Covid-19: implications for the cardiovascular system. Circulation. 2020;142:68&#x2013;78. doi: 10.1161/CIRCULATIONAHA.120.047549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047549</ArticleId><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Petramala, L. et al. Cardiomyopathies and adrenal diseases. Int. J. Mol. Sci.21, 5047 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404306</ArticleId><ArticleId IdType="pubmed">32709015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ucakturk SA, et al. Catecholamine-induced myocarditis in a child with pheochromocytoma. J. Clin. Res. Pediatr. Endocrinol. 2020;12:202&#x2013;205. doi: 10.4274/jcrpe.galenos.2019.2019.0045.</Citation><ArticleIdList><ArticleId IdType="doi">10.4274/jcrpe.galenos.2019.2019.0045</ArticleId><ArticleId IdType="pmc">PMC7291411</ArticleId><ArticleId IdType="pubmed">31208160</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YT, Wang SM, Wang JR, Yu CK, Liu CC. Norepinephrine and epinephrine enhanced the infectivity of enterovirus 71. PLoS ONE. 2015;10:e0135154. doi: 10.1371/journal.pone.0135154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135154</ArticleId><ArticleId IdType="pmc">PMC4529162</ArticleId><ArticleId IdType="pubmed">26252639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with Covid-19. J. Cardiovasc. Electrophysiol. 2020;31:1003&#x2013;1008. doi: 10.1111/jce.14479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.14479</ArticleId><ArticleId IdType="pmc">PMC7262150</ArticleId><ArticleId IdType="pubmed">32270559</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YC, et al. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc. Res. 2004;62:558&#x2013;567. doi: 10.1016/j.cardiores.2004.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2004.01.039</ArticleId><ArticleId IdType="pubmed">15158148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YC, Yin SC, Chi CS, Hwang B, Hsu SL. Norepinephrine induces apoptosis in neonatal rat endothelial cells via a Ros-dependent Jnk activation pathway. Apoptosis. 2006;11:2053&#x2013;2063. doi: 10.1007/s10495-006-0192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-006-0192-8</ArticleId><ArticleId IdType="pubmed">17041759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv XX, et al. Berberine inhibits norepinephrine-induced apoptosis in neonatal rat cardiomyocytes via inhibiting Ros-Tnf-alpha-caspase signaling pathway. Chin. J. Integr. Med. 2013;19:424&#x2013;431. doi: 10.1007/s11655-011-0856-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-011-0856-2</ArticleId><ArticleId IdType="pubmed">22382522</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors&#x2013;alterations in signal transduction and pharmacogenomics in heart failure. Nat. Clin. Pract. Cardiovasc. Med. 2005;2:475&#x2013;483. doi: 10.1038/ncpcardio0309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpcardio0309</ArticleId><ArticleId IdType="pubmed">16265588</ArticleId></ArticleIdList></Reference><Reference><Citation>Izem-Meziane M, et al. Catecholamine-induced cardiac mitochondrial dysfunction and MPTP opening: protective effect of curcumin. Am. J. Physiol. Heart Circ. Physiol. 2012;302:H665&#x2013;H674. doi: 10.1152/ajpheart.00467.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00467.2011</ArticleId><ArticleId IdType="pubmed">22101527</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaudet L, Calderari B, Pacher P. Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. Heart Fail. Rev. 2014;19:815&#x2013;824. doi: 10.1007/s10741-014-9418-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10741-014-9418-y</ArticleId><ArticleId IdType="pubmed">24398587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhang J, Beard DA. Experimentally observed phenomena on cardiac energetics in heart failure emerge from simulations of cardiac metabolism. Proc. Natl Acad. Sci. USA. 2009;106:7143&#x2013;7148. doi: 10.1073/pnas.0812768106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0812768106</ArticleId><ArticleId IdType="pmc">PMC2667147</ArticleId><ArticleId IdType="pubmed">19357309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemieux H, Semsroth S, Antretter H, Hofer D, Gnaiger E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int. J. Biochem. Cell Biol. 2011;43:1729&#x2013;1738. doi: 10.1016/j.biocel.2011.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2011.08.008</ArticleId><ArticleId IdType="pubmed">21871578</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosca M, Minkler P, Hoppel CL. Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim. Biophys. Acta. 2011;1807:1373&#x2013;1382. doi: 10.1016/j.bbabio.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2011.02.003</ArticleId><ArticleId IdType="pubmed">21320465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-Symbio: a randomized double-blind trial. JACC Heart Fail. 2014;2:641&#x2013;649. doi: 10.1016/j.jchf.2014.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2014.06.008</ArticleId><ArticleId IdType="pubmed">25282031</ArticleId></ArticleIdList></Reference><Reference><Citation>Daubert, M. A. et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ. Heart Fail.10, e004389 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29217757</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce JD, et al. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. BMC Cardiovasc. Disord. 2018;18:57. doi: 10.1186/s12872-018-0796-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0796-2</ArticleId><ArticleId IdType="pmc">PMC5879598</ArticleId><ArticleId IdType="pubmed">29606104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimbaud S, Garnier A, Ventura-Clapier R. Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol. Rep. 2009;61:131&#x2013;138. doi: 10.1016/S1734-1140(09)70015-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(09)70015-5</ArticleId><ArticleId IdType="pubmed">19307701</ArticleId></ArticleIdList></Reference><Reference><Citation>Morton DB, et al. Refining procedures for the administration of substances. Report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. British Veterinary Association Animal Welfare Foundation/Fund for the Replacement of Animals in Medical Experiments/Royal Society for the Prevention of Cruelty to Animals/Universities Federation for Animal Welfare. Lab. Anim. 2001;35:1&#x2013;41. doi: 10.1258/0023677011911345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/0023677011911345</ArticleId><ArticleId IdType="pubmed">11201285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KL, Hsu C, Chan JY. Impairment of the mitochondrial respiratory enzyme activity triggers sequential activation of apoptosis-inducing factor-dependent and caspase-dependent signaling pathways to induce apoptosis after spinal cord injury. J. Neurochem. 2007;101:1552&#x2013;1566. doi: 10.1111/j.1471-4159.2006.04445.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04445.x</ArticleId><ArticleId IdType="pubmed">17298387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KL, Chan SH, Chan JY. Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J. Neuroinflammation. 2012;9:212. doi: 10.1186/1742-2094-9-212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-212</ArticleId><ArticleId IdType="pmc">PMC3462714</ArticleId><ArticleId IdType="pubmed">22958438</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy&#x2013;a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat. Clin. Pract. Cardiovasc. Med. 2008;5:22&#x2013;29. doi: 10.1038/ncpcardio1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpcardio1066</ArticleId><ArticleId IdType="pubmed">18094670</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustino G, et al. Takotsubo cardiomyopathy in Covid-19. J. Am. Coll. Cardiol. 2020;76:628&#x2013;629. doi: 10.1016/j.jacc.2020.05.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.068</ArticleId><ArticleId IdType="pmc">PMC7279731</ArticleId><ArticleId IdType="pubmed">32517962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyanna PT, et al. Apical Takotsubo cardiomyopathy in a Covid-19 patient presenting with stroke: a case report and pathophysiologic insights. Am. J. Med. Case Rep. 2020;8:350&#x2013;357. doi: 10.12691/ajmcr-8-10-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.12691/ajmcr-8-10-8</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TD, Wu CC, Lee YT. Myocardial stunning after cerebral infarction. Int. J. Cardiol. 1997;58:308&#x2013;311. doi: 10.1016/S0167-5273(96)02879-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-5273(96)02879-3</ArticleId><ArticleId IdType="pubmed">9076560</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex stimulation. Neurology. 1992;42:1727&#x2013;1732. doi: 10.1212/WNL.42.9.1727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.9.1727</ArticleId><ArticleId IdType="pubmed">1513461</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen H, Zaroff JG. Neurogenic stunned myocardium. Curr. Neurol. Neurosci. Rep. 2009;9:486&#x2013;491. doi: 10.1007/s11910-009-0071-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-009-0071-0</ArticleId><ArticleId IdType="pubmed">19818236</ArticleId></ArticleIdList></Reference><Reference><Citation>Behmenburg F, et al. Milrinone-induced postconditioning requires activation of mitochondrial Ca(2+)-sensitive potassium (mBKCa) channels. J. Cardiothorac. Vasc. Anesth. 2018;32:2142&#x2013;2148. doi: 10.1053/j.jvca.2017.11.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2017.11.048</ArticleId><ArticleId IdType="pubmed">29306618</ArticleId></ArticleIdList></Reference><Reference><Citation>Raupach, A. et al. Milrinone-induced pharmacological preconditioning in cardioprotection: hints for a role of mitochondrial mechanisms. J. Clin. Med.8, 507 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517902</ArticleId><ArticleId IdType="pubmed">31013843</ArticleId></ArticleIdList></Reference><Reference><Citation>Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Investig. 2005;115:547&#x2013;555. doi: 10.1172/JCI24405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI24405</ArticleId><ArticleId IdType="pmc">PMC1052011</ArticleId><ArticleId IdType="pubmed">15765136</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobel B, Jequier E, Sjoerdsma A, Lovenberg W. Effect of catecholamines and adrenergic blocking agents on oxidative phosphorylation in rat heart mitochondria. Circ. Res. 1966;19:1050&#x2013;1061. doi: 10.1161/01.RES.19.6.1050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.19.6.1050</ArticleId><ArticleId IdType="pubmed">5928544</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis BC, et al. Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2015;308:H467&#x2013;H477. doi: 10.1152/ajpheart.00734.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00734.2013</ArticleId><ArticleId IdType="pubmed">25527782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi CY, et al. Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: a randomized controlled trial. Crit. Care Med. 2013;41:1754&#x2013;1760. doi: 10.1097/CCM.0b013e31828a2a85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2a85</ArticleId><ArticleId IdType="pubmed">23685637</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah HN. Targeting the mitochondria in heart failure: a translational perspective. JACC Basic Transl. Sci. 2020;5:88&#x2013;106. doi: 10.1016/j.jacbts.2019.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2019.07.009</ArticleId><ArticleId IdType="pmc">PMC7000886</ArticleId><ArticleId IdType="pubmed">32043022</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, et al. Expert Consensus Document: mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 2017;14:238&#x2013;250. doi: 10.1038/nrcardio.2016.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2016.203</ArticleId><ArticleId IdType="pmc">PMC5350035</ArticleId><ArticleId IdType="pubmed">28004807</ArticleId></ArticleIdList></Reference><Reference><Citation>Irlbeck M, Muhling O, Iwai T, Zimmer HG. Different response of the rat left and right heart to norepinephrine. Cardiovasc. Res. 1996;31:157&#x2013;162. doi: 10.1016/S0008-6363(95)00188-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0008-6363(95)00188-3</ArticleId><ArticleId IdType="pubmed">8849601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tveita T, Sieck GC. Effects of milrinone on left ventricular cardiac function during cooling in an intact animal model. Cryobiology. 2012;65:27&#x2013;32. doi: 10.1016/j.cryobiol.2012.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cryobiol.2012.03.007</ArticleId><ArticleId IdType="pubmed">22465655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, et al. Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock. Crit. Care. 2016;20:407. doi: 10.1186/s13054-016-1580-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1580-2</ArticleId><ArticleId IdType="pmc">PMC5175382</ArticleId><ArticleId IdType="pubmed">27998289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>